Please login to the form below

Not currently logged in

Daiichi Sankyo offloads stake in India's Sun Pharma

Japanese firm wants to shed its share of the generic Indian drugmaker

Daiichi Sankyo logo 

Daiichi Sankyo has found a buyer for its $3.6bn holding in India's Sun Pharmaceutical almost immediately after putting the stake up for sale.

Yesterday, the Japanese pharma company said it planned to sell all or part of the shares it held in Sun, which were acquired after the completion of the merger between the Indian firm and Daiichi Sankyo's Ranbaxy unit last month.

Around 215 million shares held by Daiichi Sankyo - equivalent to around 9% of Sun Pharma's total shares - were sold off in a series of block transactions yesterday at an 11% discount to its previous closing share price, putting pressure on the stock which fell more than 10% yesterday.

The share sale brings a turbulent chapter in Daiichi Sankyo's history to a close as it disposes of an asset which has weighed heavily on its operations for several years. 

The Japanese firm bought a two-thirds share in Ranbaxy for $4.7bn in 2008, hoping to tap into the growth for generic medicines in emerging markets. 

However, the Indian firm was almost immediately beset by a series of quality problems at manufacturing facilities which led to some of its products being blocked for import into the US, EU and other markets, and eventually resulted in a $500m fine by the US authorities in 2013.

Problems have continued since the fine, however. Last December, a fresh ban was imposed by the EU on a cephalosporin antibiotic made at a Ranbaxy plant that failed a Good Manufacturing Practice (GMP) inspection, while a plant making active pharmaceutical ingredients (API) fell afoul of an FDA audit earlier in 2014.

Daiichi Sankyo investors seemed to welcome the end of the saga, with shares in the company gaining almost 3% yesterday after news of the sale emerged.

The merger of Sun and Ranbaxy created the world's fifth largest speciality generic pharmaceutical company and India's biggest drugmaker.

Article by
Ben Adams

21st April 2015

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...